YZYi Zhou

Yi Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi Zhou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Haiqing Zhong

    Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China

    1 shared publication
  • Honghui Wu

    Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China

    1 shared publication
  • Jianqing Gao

    Zhejiang University

    1 shared publication
  • Linjie Wu

    Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China

    1 shared publication
  • Mengting Lin

    Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China

    1 shared publication
  • Min Han

    Zhejiang University

    1 shared publication

Latest Publications

  • Open Access

    Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche

    by Yi Zhou, Peng Ke, Xiaoyan Bao, Honghui Wu, Yiyi Xia, Zhentao Zhang, Haiqing Zhong, Qi Dai, Linjie Wu, Tiantian Wang, et al.

    There is evidence to suggest that the primary tumor induces the formation of a pre-metastatic niche in distal organs by stimulating the production of pro-metastatic factors. Given the fundamental role of the pre-metastatic niche in the development of metastases, interruption of its formation would be a promising strategy to take early action against tumor metastasis. Here we report an enzyme-activated assembled peptide FR17 that can serve as a “flame-retarding blanket” in the pre-metastatic niche specifically to extinguish the “fire” of tumor-supportive microenvironment adaption. We show that the in-situ assembled peptide nano-blanket inhibits fibroblasts activation, suppressing the remodeling of the metastasis-supportive host stromal tissue, and reversing vascular destabilization and angiogenesis. Furthermore, we demonstrate that the nano-blanket prevents the recruitment of myeloid cells to the pre-metastatic niche, regulating the immune-suppressive microenvironment. We show that FR17 administration effectively inhibits the formation of the pulmonary pre-metastatic niche and postoperative metastasis, offering a therapeutic strategy against pre-metastatic niche formation.